The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The technique of transplanting progenitor cells into a region of damaged myocardium, termed cellular cardiomyoplasty, is a potentially new therapeutic modality designed to replace or repair necrotic, scarred, or dysfunctional myocardium. Ideally, graft cells should be readily available, easy to culture to ensure adequate quantities for transplantation, and able to survive in host myocardium; often a hostile environment of limited blood supply and immunorejection. Whether effective cellular regenerative strategies require that administered cells differentiate into adult cardiomyocytes and couple electromechanically with the surrounding myocardium is increasingly controversial, and recent evidence suggests that this may not be required for effective cardiac repair. Most importantly, transplantation of graft cells should improve cardiac function and prevent adverse ventricular remodeling. To date, a number of candidate cells have been transplanted in experimental models, including fetal and neonatal cardiomyocytes, embryonic stem cell-derived myocytes, tissue engineered contractile grafts, skeletal myoblasts, several cell types derived from adult bone marrow, and cardiac precursors residing within the heart itself. There has been substantial clinical development in the use of whole bone marrow and skeletal myoblast preparations in studies enrolling both post-infarction patients, and patients with chronic ischemic left ventricular dysfunction and heart failure. The effects of bone-marrow derived mesenchymal stem cells (MSCs) have also been studied clinically.
Currently, bone marrow or bone marrow-derived cells represent highly promising modality for cardiac repair. The totality of evidence from trials investigating autologous whole bone marrow infusions into patients following myocardial infarction supports the safety of this approach. In terms of efficacy, increases in ejection fraction are reported in the majority of the trials.
Chronic ischemic left ventricular dysfunction resulting from heart disease is a common and problematic condition; definitive therapy in the form of heart transplantation is available to only a tiny minority of eligible patients. Cellular cardiomyoplasty for chronic heart failure has been studied less than for acute MI, but represents a potentially important alternative for this disease.
| Condition | Intervention | Phase |
|---|---|---|
|
Stem Cell Transplantation |
Biological: Auto-hMSCs Biological: Allo-hMSCs |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction |
- Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation [ Time Frame: One month post-catheterization ] [ Designated as safety issue: Yes ]
- CT Infarct Size From Early Enhanced Defect: - Difference Between the Baseline and 13-month [ Time Frame: Baseline Month 13 post-catheterization ] [ Designated as safety issue: No ]Percentage change from 13-months post-catheterization to baseline.
- CT Measure of Left Ventricular Ejection Fraction [ Time Frame: Baseline Month 13 post-catheterization ] [ Designated as safety issue: No ]
- CT Measure of End Diastolic Volume [ Time Frame: Baseline Month 13 post-catheterization ] [ Designated as safety issue: No ]
- CT Measure of End Systolic Volume [ Time Frame: Baseline Month 13 post-catheterization ] [ Designated as safety issue: No ]
- CT Measure of Scar Size as % of LV Mass [ Time Frame: Baseline Month 13 post-catheterization ] [ Designated as safety issue: No ]
- Change in Distance Walked in 6-minutes From Baseline. [ Time Frame: 12-months ] [ Designated as safety issue: No ]
- Change in Minnesota Living With Heart Failure Total Score [ Time Frame: 12 months ] [ Designated as safety issue: No ]The Minnesota living with heart failure questionnaire uses a 6-point, zero to five, Likert scale. The total score is the sum of the 21 responses. The total score is considered the best measure of how heart failure and treatments impact a patients quality of life. The max score is 105, minimum score is 0. A lower score is considered a better quality of life.
- Change in New York Heart Association Class at 12-months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
| Enrollment: | 31 |
| Study Start Date: | March 2010 |
| Study Completion Date: | October 2012 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Auto-hMSCs
Participants will receive an injection of 20 million, 100 million or 200 million autologous human mesenchymal stem cells.
|
Biological: Auto-hMSCs
Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
|
|
Experimental: Allo-hMSCs
Participants will receive an injection of 20 million, 100 million or 200 million allogeneic human mesenchymal stem cells.
|
Biological: Allo-hMSCs
Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
|
Eligibility| Ages Eligible for Study: | 21 Years to 90 Years (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of chronic ischemic left ventricular dysfunction secondary to MI.
- Be a candidate for cardiac catheterization.
- Been treated with appropriate maximal medical therapy for heart failure or post-infarction left ventricular dysfunction.
- Ejection fraction between 20% and 50%.
- Able to perform a metabolic stress test.
Exclusion Criteria:
- Baseline glomerular filtration rate <50 ml/min/1.73m2.
- Presence of a mechanical aortic valve or heart constrictive device.
- Documented presence of aortic stenosis (aortic stenosis graded as ≥+2 equivalent to an orifice area of 1.5cm2 or less).
- Documented presence of moderate to severe aortic insufficiency (echocardio- graphic assessment of aortic insufficiency graded as ≥+2).
- Evidence of a life-threatening arrhythmia (nonsustained ventricular tachycardia ≥20 consecutive beats or complete heart block) or QTc interval >550 ms on screening ECG. In addition; patients with sustained or a short run of ventricular tachycardia on ECG or 48 hour Ambulatory ECG during the screening period will be removed from the protocol.
- Documented unstable angina.
- AICD firing in the past 60 days prior to the procedure.
- Be eligible for or require coronary artery revascularization.
- Have a hematologic abnormality as evidenced by hematocrit < 25%, white blood cell < 2,500/ul or platelet values < 100,000/ul without another explanation.
- Have liver dysfunction, as evidenced by enzymes (ALT and AST) greater than three times the ULN.
- Have a coagulopathy condition = (INR > 1.3) not due to a reversible cause.
- Known, serious radiographic contrast allergy.
- Known allergies to penicillin or streptomycin.
- Organ transplant recipient.
- Clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.
- Non-cardiac condition that limits lifespan to < 1 year.
- On chronic therapy with immunosuppressant medication.
- Serum positive for HIV, hepatitis BsAg, or hepatitis C.
- Female patient who is pregnant, nursing, or of child-bearing potential and not using effective birth control.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01087996
| United States, Florida | |
| University of Miami Miller School of Medicine | |
| Miami, Florida, United States | |
| United States, Maryland | |
| Johns Hopkins University | |
| Baltimore, Maryland, United States | |
| Principal Investigator: | Joshua M Hare, MD | University of Miami |
More Information
Publications:
| Responsible Party: | Joshua M Hare, Director, Interdisciplinary Stem Cell Institute, University of Miami |
| ClinicalTrials.gov Identifier: | NCT01087996 History of Changes |
| Other Study ID Numbers: | 20090352 R01HL110737 R01HL107110 R01HL084275 P20HL101443 R01HL094849 |
| Study First Received: | March 15, 2010 |
| Results First Received: | August 30, 2013 |
| Last Updated: | May 21, 2015 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by University of Miami:
|
Chronic Ischemic Left Ventricular |
ClinicalTrials.gov processed this record on September 30, 2016